Pulse Biosciences recently announced that its pivotal NANOPULSE-AF Study has reached full enrollment of 164 evaluable ...

- Pulse Biosciences PLSE+7.66% (PLSE) surged 7.7% to $53.80 after completing its NANOPULSE-AF trial enrollment three months ...

Boston is seeking an injunction and damages regarding alleged patent infringement relating to J&J subsidiary Atraverse's Hotwire system.

Thermedical ®, a developer of advanced thermal-ablation technologies, today announced the members of the independent data safety monitoring board (DSMB), clinical events committee (CEC) and arrhythmia ...

A 62-year-old woman with recurrent atrial fibrillation and hypertrophic obstructive cardiomyopathy underwent pulse field ...

The Kailua hospital secured exclusive access to the Volt Pulsed Field Ablation system to treat atrial fibrillation, targeting ...

The Heart After One Year~348 Days Since Discharge~At my last check-up, the doctor told me:"Let's do some final tests and work ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that its NANOPULSE-AF Study ...

Samsung Medical Center has performed South Korea's first dual-energy ablation, combining pulsed-field and radiofrequency ...

Pulse Biosciences, Inc. announced that its NANOPULSE-AF Study has reached its enrollment target of 164 evaluable patients across 15 clinical sites. The NANOPULSE-AF Study is a prospective, multicenter ...

A new study published in the journal of Heart Rhythm O2 showed that performing right atrial (RA) linear ablation with a ...

A rare case report shows that an epicardial muscular connection bypassing ablation scars drove atrial fibrillation recurrence ...